Serum levels and genetic variation of TGF‐β1 are not associated with Alzheimer's disease

E Rodríguez‐Rodríguez… - Acta neurologica …, 2007 - Wiley Online Library
E Rodríguez‐Rodríguez, P Sánchez‐Juan, I Mateo, J Llorca, J Infante, I García‐Gorostiaga…
Acta neurologica scandinavica, 2007Wiley Online Library
Objective–As transforming growth factor‐β1 (TGF‐β1) determines important neurotrophic
and neuroprotective actions, we postulated serum TGF‐β1 levels could be low in
Alzheimer's disease (AD), and TGF‐β1 genetic variation could be associated with AD risk
through modulating serum TGF‐β1 levels. Methods–TGF‐β1 (− 800)(rs 1800468),(− 509)(rs
1800469) and (+ 869)(rs 1982073) polymorphisms were genotyped in 412 AD patients and
406 controls. We measured serum TGF‐β1 levels (by ELISA) in 63 AD patients and …
Objective –  As transforming growth factor‐β1 (TGF‐β1) determines important neurotrophic and neuroprotective actions, we postulated serum TGF‐β1 levels could be low in Alzheimer’s disease (AD), and TGF‐β1 genetic variation could be associated with AD risk through modulating serum TGF‐β1 levels.
Methods –  TGF‐β1 (−800) (rs 1800468), (−509) (rs 1800469) and (+869) (rs 1982073) polymorphisms were genotyped in 412 AD patients and 406 controls. We measured serum TGF‐β1 levels (by ELISA) in 63 AD patients and compared them with 77 age‐ and gender‐matched non‐demented controls.
Results –  Serum TGF‐β1 levels were not different in AD patients than in controls. Distribution of the allele and genotype frequencies of TGF‐β1 polymorphisms did not differ between AD patients and controls. There was no significant correlation between serum TGF‐β1 levels and TGF‐β1 polymorphisms.
Conclusion –  Serum TGF‐β1 concentration is not a potential biomarker for AD, and TGF‐β1 genetic variants (−800, −509, and +869) are not risk factors for AD.
Wiley Online Library